China’s medical research: what the 2026 Nature Index shows

Where does China stand in the latest health-sciences table?

The Nature Index 2026 Research Leaders table uses publications from January to December 2025. In health sciences, the United States ranks first by Share at 8,690.53, followed by China at 7,321.82. The UK, Germany, France and Japan also appear among the leading contributors.

The table reports 8,461 articles with Chinese institutional contributions. This is Count within the selected Nature Index publications, not the total number of medical papers published by China. Internationally co-authored articles can contribute to more than one country’s Count.

Sources: [1], [2]

What do Share and Count actually measure?

Count records articles with an institution or country affiliation. Share allocates fractional article contributions. Nature Index covers a selected set of publications; it does not measure all medical literature, all clinical activity or outcomes from treating patients.

Nature’s methodology cautions that institutional size and research mix affect output and are not normalized away. A large Share is evidence of research contribution in this database. It is not a patient-outcome score, a licensing credential or evidence that every doctor in an institution is equally suitable.

Sources: [2]

Which Chinese institutions are visible internationally?

In the 2026 health-sciences institution table, seven of the top ten institutions are in China. These include the Chinese Academy of Sciences, Shanghai Jiao Tong University, Zhejiang University, Fudan University, Sun Yat-sen University, Sichuan University and Peking University.

That is a map of research institutions, not a list of available clinical appointments. A university may include many affiliated hospitals and departments; the Chinese Academy of Sciences is not an interchangeable hospital booking option. Confirm the actual treating institution and specialist separately.

Sources: [3]

Look for expertise connected to your particular question

A useful specialist profile connects clinical work with checkable evidence. Rather than counting publications alone, look for papers on the disease, diagnostic uncertainty or treatment decision you want reviewed. Check whether the doctor contributed, which institution is listed and whether the study applies to the relevant patient group.

• Start with the doctor’s current hospital profile and actual clinical specialty.
• Check the original paper, author affiliation and publication date; name matches alone can be misleading.
• Distinguish laboratory research, observational studies, clinical trials and guidelines.
• Ask how the specialist’s clinical experience relates to your records and decision.
• Confirm provider acceptance, report format and follow-up responsibilities before committing.

What advantage can this offer an overseas patient?

Our interpretation is that a substantial academic research base expands the specialist teams an overseas patient can investigate. A relevant second opinion may help you formulate questions for your current treating team, whether it supports the existing plan or identifies a need for further assessment.

China Heal Plus helps coordinate that enquiry and identify suitable specialist options. The research figures do not guarantee acceptance, a different diagnosis, a better outcome or a lower price. Your quote and the reviewing professional’s confirmed scope define the service you receive.